Influenza vaccination of HIV‐1‐positive and hiv‐1‐negative former intravenous drug users

• DOI: 10.1002/jmv.2085
• Publication Date: 2002-08-25T21:17:12Z
• Authors: Antonella Amendola; Antonio Boschini; Daniela Colzani; Giovanni Anselmi; Arianna Oltolina; Roberta Zucconi; Marco Begnini; Silvia Besana; Elisabetta Tanzi; Alessandro Remo Z...
• Keywords: Adult; Male; Adolescent; HIV Infections; Hemagglutination Inhibition Tests; Middle Aged; Antibodies, Viral; Orthomyxoviridae; CD4 Lymphocyte Count; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Proviruses; Influenza Vaccines; HIV Seronegativity; DNA, Viral; HIV Seropositivity; Influenza, Human; HIV-1; Humans; RNA, Viral; Female; Substance Abuse, Intravenous

Abstract The immunogenicity of an anti‐influenza vaccine was assessed in 409 former intravenous drug user volunteers and its effect on the levels HIV‐1 RNA, proviral DNA CD4+ lymphocyte counts a subset HIV‐1‐positive subjects measured. individuals (n = 72) were divided into three groups basis their counts, while 337 HIV‐1‐negative participants allocated group four. Haemagglutination inhibiting (HI) responses varied from 45.8 to 70% significantly higher four (80.7% H1N1 strain, 81.6% H3N2 83% B strain). percentage with HI protective antibody titres (≥ 1:40) increased after vaccination, especially uninfected subjects. Immunization caused no significant changes neither plasma RNA nor levels. Therefore, vaccination against influenza may benefit persons infected by HIV‐1. J. Med. Virol. 65:644–648, 2001. © 2001 Wiley‐Liss, Inc.